Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.

By G. Targher, Christopher D. Byrne, A. Lonardo, G. Zoppini, C. Barbui. Journal of Hepatology, 2016

1,217 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020, neutral): “7 Furthermore, risk of incident CVD events appeared to increase further with greater severity of NAFLD (random-effects OR 2.58; 95% CI 1.78 to 3.75) (figure 2), and remained statistically significant in those studies where analysis was fully adjusted for established CVD risk factors.”
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases (2017, background): “68 This meta-analysis concluded that the presence of NAFLD (diagnosed by imaging or histology) conferred an OR of 1.64 for fatal and non-fatal incident CVD events, a risk that appeared to increase further with greater severity of NAFLD and remained signi ﬁ cant in only those studies where analysis…”
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. (2019, background): “4 INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is a common complication of obesity, and is associated with multi-organ insulin-resistance (1, 2), dyslipidemia (high plasma triglyceride and low HDL-cholesterol concentrations) (3, 4), and an increased risk of diabetes and coronary heart disea”